Results of Gazyva vs. Rituxan in CLL Trial Announced

Share this article:

Genentech announced positive data from a second stage, Phase 3 CLL11 study comparing Gazyva (obinutuzumab) to Rituxan (rituximab), both in combination with chlormabucil for people with previously untreated chronic lymphocytic leukemia (CLL) and co-existing medical conditions. 

Related: Hematologic Cancers Resource Center

Gazyva is a new monoclonal antibody designed to attach to CD20 and attack targeted cells both directly and together with the body's immune system.

CLL11 is a multicenter, open-label, randomized three-arm study investigating the efficacy and safety profile of Gazyva plus chlorambucil, Rituxan plus chlorambucil and chlorambucil alone in 781 previously untreated people with CLL and co-existing medical conditions who are in need of therapy. 

Stage 1 (n=589) compared Gazyva plus chlorambucil to chlorambucil alone and Rituxan plus chlorambucil to chlorambucil alone. Stage 2 (n=663) compared Gazyva plus chlorambucil directly with Rituxan plus chlorambucil. The primary endpoint of the study was progression-free survival (PFS).

In the Stage 2 study, patients in the Gazyva arm achieved a median PFS of 26.7 months compared with 15.2 months for those in the Rituxan arm (HR 0.39, CI 0.31-0.49, P<0.0001). 

A comparison of data from the Gazyva and Rituxan treatment arms showed higher complete response rates (21% compared with 7%) and a ten-fold increase in the percentage of people achieving minimal residual disease (MRD) negativity (29.4% compared with 2.5%), defined as no detectable disease in the blood at the end of the treatment course.

An updated analysis from the first stage (Stage 1a) of the CLL11 study showed that people treated with Gazyva in combination with chlorambucil lived longer (overall survival, or OS) compared to chlorambucil alone (HR 0.41, 95% CI 0.23-0.74, P=0.002). Given the median observation time of 23 months, median overall survival has not yet been reached in any of the study arms.

Previously the FDA granted Gazyva Breakthrough Therapy Designation and approved its use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia (CLL).

For more information call (800) 821-8590 or visit Gazyva.com.

Share this article:

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

CTA Community Poll

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Hematologic Cancers

FDA Expands Ibrutinib Use in Chronic Lymphocytic Leukemia

FDA Expands Ibrutinib Use in Chronic Lymphocytic Leukemia

People with chronic lymphocytic leukemia and 17p deletion can now get the therapy.

FDA Approves Zydelig for Three Hematologic Cancers

FDA Approves Zydelig for Three Hematologic Cancers

The FDA has approved Zydelig for relapsed chronic lymphocytic leukemia, follicular B-cell non-Hodgkin lymphoma, and small lymphocytic lymphoma.

Early Stem-Cell Transplantation, Ongoing Therapy Increase Survival in Multiple Myeloma

Early Stem-Cell Transplantation, Ongoing Therapy Increase Survival in ...

Patients with multiple myeloma experienced survival benefits when treated autologous stem-cell transplantation after induction therapy.